In this study, we aimed to reveal the mechanisms underlying the tumor-promoting effects of 3MC in RECs, with a particular focus on HIF1α/HDAC1 and RhoA, and to determine whether simvastatin can prevent these effects. The gene discussed is HDAC1; the disease is neoplasm.